| Project/Area Number |
16592011
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Surgical dentistry
|
|---|
| Research Institution | Nara Medical University |
|---|
Principal Investigator |
YAMAMOTO Kazuhiko Nara Medical University, Department of Oral and Maxillofacial Surgery, Assistant professor, 医学部, 講師 (20243842)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
DENDA Ayumi Nara Medical University, Department of Molecular Pathology, Assistant professor, 医学部, 講師 (90110858)
KIRITA Tadaaki Nara Medical University, Department of Oral and Maxillofacial Surgery, Professor, 医学部, 教授 (70201465)
|
|---|
| Project Period (FY) |
2004 – 2005
|
| Project Status |
Completed (Fiscal Year 2005)
|
| Budget Amount *help |
¥3,400,000 (Direct Cost: ¥3,400,000)
Fiscal Year 2005: ¥1,200,000 (Direct Cost: ¥1,200,000)
Fiscal Year 2004: ¥2,200,000 (Direct Cost: ¥2,200,000)
|
|---|
| Keywords | 4-nitroquinoline 1-oxide / etodolac / cyclooxygenase-2 / chemoprevention / tongue cancer / rat / receptor for advanced glycation end products / receptor for advanced glycation end products / nimesulide |
|---|
| Research Abstract |
We analyzed the effect of a selective cyclooxygenase (COX)-2 inhibitors, etodolac, on the expression of COX-2 and receptor for advanced glycation end products (RAGE) in the rat model of tongue carcinogenesis using 4-nitroquinoline 1-oxide (4-NQO).
Fischer 344 rats, 6-week-old, were administered 4-NQO (30ppm) for 12 weeks and then etodolac (150ppm and 300ppm) was given for 16 weeks. The lesions developed were histologically classified into hyperplasia, dysplaisa, pappiloma and squamous cell carcinoma (SCC).
The incidence of SCC was decreased significantly by 300ppm etodolac. Immunohistochemically, COX-2 was positive for basal cells in hyperplasia and papilloma, and for basal cells, dysplastic cell and cancer cells in dysplasia and SCC. On the other hand, RAGE was weakly and moderately positive for granular cells in hyperplasia and papilloma, and positive for dysplastic cells and cancer cells in dysplasia and SCC. Etodolac did not decrease the expression of COX-2 in these lesions but decreased the expression of RAGE. The analysis of RAGE mRNA using RT-PCR revealed that RAGE mRNA was expressed in SCC and the treatment by etodolac decreased the expression.
These results indicate that the expression of COX-2 and RAGE is closely related and the inhibitory effect by etodolac is associated with the decrease of RAGE mRNA expression in rat tongue carcinogenesis by 4-NQO.
|
